Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 06:30PM GMT
Cory William Kasimov - JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Great. Good afternoon, and welcome back to the 48th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm a Senior Large-cap Biotech Analyst, and it's my pleasure to introduce BioMarin, and Chairman and CEO, J.J. Bienaimeé. (Operator Instructions)

So with that, J.J., thanks, as always, for being here. Thanks as well for putting out some good data ahead of the conference. Let me turn things over to you for an update.

Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO

Okay. Thank you, Cory. And I'm on Slide 1 here because I cannot actually see the slides that are on the screen for you. So thank you for listening today. So I'm moving to Slide 2 of the presentation that has a safe harbor statements. I just wish to highlight that I and some of our other BioMarin's executives might be making some forward-looking statements during this Zoom call. So please refer to our filings with the SEC for more information.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot